Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.07 percent. This is a 35.19 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $(257.000 thousand) which missed the analyst consensus estimate of $2.960 million by 108.68 percent. This is a 103.02 percent decrease over sales of $8.513 million the same period last year.